750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development by Seiwert, S.D., Andrews, S.W., Tan, H., Wang, T., Marafino, B., Rieger, R., Pheneger, J., Lee, P.A., Jiang, Y., Kennedy, A.L., Ballard, J., Zhang, H., Bernat, B., Condrosld, K.R., Lemieux, C., Brandhuber, B., Josey, J.A., Blatt, L.M.

Get full text